Lisa G Rider

List of Publications by Year
in descending order

198 papers	15,260 citations	15495 65 h-index	19726 117 g-index
209 all docs	209 docs citations	209 times ranked	9222 citing authors

#	Article	IF	Citations
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
2	Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry. Journal of the American College of Cardiology, 1998, 31, 1658-1666.	1.2	700
3	Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Research, 2010, 20, 170-179.	2.4	569
4	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
5	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
6	A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis and Rheumatism, 2006, 54, 3682-3689.	6.7	418
7	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 929-936.	1.5	391
8	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391
9	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet, The, 2008, 371, 2201-2212.	6.3	383
10	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, 2004, 43, 49-54.	0.9	311
11	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (CâEHAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SFâ€36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. Arthritis Care and Research, 2011, 63, S118-57.	1.5	288
12	Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. British Journal of Rheumatology, 2001, 40, 1262-1273.	2.5	270
13	The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 223-243.	0.4	224
14	Predictors of Clinical Improvement in RituximabâEtreated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	2.9	210
15	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.5	209
16	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research, 2010, 62, 465-472.	1.5	204
17	International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis and Rheumatism, 2004, 50, 2281-2290.	6.7	202
18	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2004, 50, 1595-1603.	6.7	195

#	Article	IF	Citations
19	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis and Rheumatism, 1999, 42, 2213-2219.	6.7	194
20	Modes of action of aspirin-like drugs.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 7227-7231.	3.3	184
21	Postlicensure Safety Surveillance for Varicella Vaccine. JAMA - Journal of the American Medical Association, 2000, 284, 1271.	3.8	182
22	Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Lancet, The, 2000, 356, 2155-2156.	6.3	173
23	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. American Journal of Human Genetics, 2012, 90, 217-228.	2.6	168
24	Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis and Rheumatism, 2003, 48, 2285-2293.	6.7	167
25	Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. Annals of Internal Medicine, 1995, 122, 715.	2.0	150
26	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 52, 2607-2615.	6.7	146
27	The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 25-41.	0.4	145
28	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
29	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2006, 85, 111-127.	0.4	140
30	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine (United States), 2008, 87, 70-86.	0.4	137
31	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. Arthritis and Rheumatism, 2000, 43, 1866-1873.	6.7	132
32	CLASSIFICATION AND TREATMENT OF THE JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES. Rheumatic Disease Clinics of North America, 1997, 23, 619-655.	0.8	128
33	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis and Rheumatism, 1997, 40, 1976-1983.	6.7	127
34	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.5	127
35	Defining Clinical Improvement in Adult and Juvenile Myositis. Journal of Rheumatology, 2003, 30, 603-17.	1.0	124
36	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	1.8	121

#	Article	IF	Citations
37	The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. Journal of Internal Medicine, 2016, 280, 24-38.	2.7	117
38	Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies. JAMA - Journal of the American Medical Association, 2011, 305, 183.	3.8	115
39	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
40	Genomeâ€Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
41	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.5	109
42	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
43	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity, 2015, 16, 470-480.	2.2	103
44	Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Practice and Research in Clinical Rheumatology, 2009, 23, 665-678.	1.4	102
45	Update on outcome assessment in myositis. Nature Reviews Rheumatology, 2018, 14, 303-318.	3.5	100
46	Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology, 2009, 48, 134-139.	0.9	99
47	Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis. Journal of Pediatrics, 2012, 160, 520-522.	0.9	99
48	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2019, 78, 988-995.	0.5	99
49	A broadened spectrum of juvenile myositis. myositis-specific autoantibodies in children. Arthritis and Rheumatism, 1994, 37, 1534-1538.	6.7	96
50	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2005, 84, 338-349.	0.4	92
51	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.5	92
52	Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2000, 12, 482-491.	2.0	86
53	Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis and Rheumatism, 2002, 46, 1885-1893.	6.7	86
54	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	1.5	84

#	Article	IF	Citations
55	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.5	81
56	Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 3941-3950.	6.7	80
57	The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis. Current Rheumatology Reports, 2014, 16, 467.	2.1	79
58	HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis and Rheumatism, 2006, 54, 3670-3681.	6.7	78
59	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2010, 62, 219-225.	1.5	77
60	Developments in the Classification and Treatment of the Juvenile Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 2013, 39, 877-904.	0.8	74
61	Association of Antiâ€“3â€Hydroxyâ€3â€Methylglutarylâ€Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care and Research, 2017, 69, 1088-1094.	1.5	71
62	Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clinical and Experimental Immunology, 2000, 121, 47-52.	1.1	69
63	Endothelial cell activation and neovascularization are prominent in dermatomyositis. Journal of Autoimmune Diseases, 2006, 3, 2.	1.0	69
64	Early Illness Features Associated With Mortality in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2014, 66, 732-740.	1.5	68
65	Diagnostic criteria for polymyositis and dermatomyositis. Lancet, The, 2003, 362, 1762-1763.	6.3	67
66	Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis and Rheumatism, 2006, 54, 3979-3987.	6.7	66
67	Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis and Rheumatism, 1998, 41, 710-719.	6.7	65
68	Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatric Rheumatology, 2017, 15, 1.	0.9	65
69	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5, .	2.3	65
70	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
71	Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. Arthritis and Rheumatism, 1999, 42, 1285-1290.	6.7	58
72	Brief Report: Ultraviolet Radiation Exposure Is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis. Arthritis and Rheumatism, 2013, 65, 1934-1941.	6.7	58

#	Article	IF	Citations
73	Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e59-e59.	3.7	58
74	Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology, 2001, 40, 1279-1284.	0.9	55
75	Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis and Rheumatism, 2007, 56, 2719-2728.	6.7	55
76	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis and Rheumatism, 2007, 57, 881-884.	6.7	55
77	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2021, 80, 406-408.	0.5	53
78	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	2.9	52
79	Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 59, 214-221.	6.7	51
80	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.5	51
81	Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheumatic Disease Clinics of North America, 2002, 28, 935-977.	0.8	49
82	Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity. Journal of Pediatrics, 2001, 138, 942-945.	0.9	48
83	The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology, 2007, 46, 1606-1611.	0.9	48
84	Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatology Journal, 2012, 6, 54-63.	0.1	48
85	Decreased aerobic capacity in children with juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 47, 118-123.	6.7	47
86	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology, 2017, 56, 1342-1347.	0.9	46
87	Idiopathic Inflammatory Myopathies. , 2008, , 368-374.		45
88	Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology, 2010, 49, 2381-2390.	0.9	44
89	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2008, 58, 3239-3246.	6.7	43
90	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis and Rheumatology, 2016, 68, 761-768.	2.9	43

#	Article	IF	Citations
91	Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging.. Radiology, 1998, 209, 191-196.	3.6	42
92	Novel gastrointestinal tract manifestations in juvenile dermatomyositis. Journal of Pediatrics, 1999, 135, 371-374.	0.9	42
93	Idiopathic inflammatory muscle disease: clinical aspects. Best Practice and Research in Clinical Rheumatology, 2000, 14, 37-54.	1.4	42
94	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskeletal Disorders, 2015, 16, 257.	0.8	42
95	Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis and Rheumatism, 2004, 51, 365-370.	6.7	41
96	Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Annals of the Rheumatic Diseases, 2013, 72, 350-356.	0.5	41
97	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology, 2016, 55, kev344.	0.9	41
98	Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. Autoimmunity Reviews, 2020, 19, 102533.	2.5	41
99	2015 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis and Rheumatology, 2015, 67, 1-4046.	2.9	40
100	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	0.9	40
101	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Research and Therapy, 2020, 22, 69.	1.6	39
102	HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis and Rheumatism, 2003, 48, 2567-2572.	6.7	37
103	Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats. Arthritis and Rheumatism, 2008, 59, 352-356.	6.7	37
104	Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Research and Therapy, 2011, 13, R69.	1.6	37
105	The heterogeneity of juvenile myositis. Autoimmunity Reviews, 2007, 6, 241-247.	2.5	36
106	Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2009, 11, R159.	1.6	36
107	Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2016, 75, 1599-1606.	0.5	36
108	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.5	36

#	Article	IF	Citations
109	Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 53, 565-570.	6.7	35
110	Pediatric Rheumatology Collaborative Study Group â€“ over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatric Rheumatology, 2018, 16, 45.	0.9	35
111	Assessment of disease activity and its sequelae in children and adults with myositis. Current Opinion in Rheumatology, 1996, 8, 495-506.	2.0	34
112	Virus-mediated autoimmunity in Multiple Sclerosis. Journal of Autoimmune Diseases, 2006, 3, 1.	1.0	33
113	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€”methodological aspects. Rheumatology, 2017, 56, 1884-1893.	0.9	33
114	Predictors of Reduced Healthâ€Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2017, 69, 1743-1750.	1.5	32
115	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2018, 77, 714-719.	0.5	31
116	Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clinical Chemistry, 2002, 48, 1681-8.	1.5	31
117	Gingival and Periungual Vasculopathy of Juvenile Dermatomyositis. New England Journal of Medicine, 2009, 360, e21.	13.9	30
118	Parvovirus B19 and Onset of Juvenile Dermatomyositis. JAMA - Journal of the American Medical Association, 2005, 294, 2165.	3.8	29
119	Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. Journal of Pediatrics, 1991, 118, 417-419.	0.9	28
120	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2020, 72, 1945-1951.	2.9	28
121	Polymyositis: An overdiagnosed entity. Neurology, 2004, 63, 402-403.	1.5	27
122	Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis. Journal of Pediatrics, 2009, 155, 882-887.	0.9	27
123	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Research and Therapy, 2020, 22, 117.	1.6	27
124	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.4	25
125	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology, 2021, 60, 1839-1849.	0.9	25
126	Intra-Rater and Inter-Rater Reliability of the 10-Point Manual Muscle Test (MMT) of Strength in Children with Juvenile Idiopathic Inflammatory Myopathies (JIIM). Physical and Occupational Therapy in Pediatrics, 2006, 26, 5-17.	0.8	24

#	Article	IF	Citations
127	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology, 2018, 57, 1956-1963.	0.9	24
128	Cerebrospinal fluid analysis in children with seizures. Pediatric Emergency Care, 1995, 11, 226-229.	0.5	23
129	Walking ability and its relationship to lower extremity muscle strength in children with idiopathic inflammatory myopathies11The opinions expressed in this article reflect the views of the authors and are not necessarily those of the National Institutes of Health and the US Public Health Service.No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the author(s) or on any organization with which the author(s) is/are asso. Archives of Physical Medicine and Rehabilitation, 2004, 85, 767-771.	0.5	22
130	Juvenile Dermatomyositis. , 2016, , 351-383.e18.		22
131	Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. British Journal of Dermatology, 2017, 177, 1086-1092.	1.4	22
132	Fitness as a Determinant of the Oxygen Uptake/Work Rate Slope in Healthy Children and Children With Inflammatory Myopathy. Applied Physiology, Nutrition, and Metabolism, 2003, 28, 888-897.	1.7	21
133	Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Research, 2013, 65, 1969-1975.	1.5	21
134	Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?. BMJ Open, 2015, 5, e006636-e006636.	0.8	21
135	Long-term outcomes in Juvenile Myositis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 149-155.	1.6	21
136	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€“20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.3	19
137	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research, 2020, 72, 1636-1644.	1.5	19
138	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, .	0.2	19
139	Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskeletal Disorders, 2014, 15, 67.	0.8	18
140	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. Journal of Rheumatology, 2020, 47, 1011-1018.	1.0	17
141	JUVENILE DERMATOMYOSITIS. , 2011, , 375-413.		16
142	Myositis registries and biorepositories. Current Opinion in Rheumatology, 2014, 26, 724-741.	2.0	16
143	Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. PLoS ONE, 2015, 10, e0142486.	1.1	16
144	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	1.6	16

#	Article	IF	Citations
145	Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology, 2021, 60, 829-836.	0.9	15
146	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S70-S71.	2.9	14
147	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. Journal of Rheumatology, 2016, 43, 169-176.	1.0	14
148	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. Clinical Rheumatology, 2021, 40, 4095-4100.	1.0	14
149	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clinical and Experimental Rheumatology, 2014, 32, 689-96.	0.4	14
150	Pulmonary hypertension in a seventeen-year-old boy. Journal of Pediatrics, 1992, 120, 149-159.	0.9	13
151	Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*. Arthritis Research and Therapy, 2011, 13, R181.	1.6	13
152	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Scientific Reports, 2020, 10, 4462.	1.6	13
153	Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Physical and Occupational Therapy in Pediatrics, 2006, 26, 5-17.	0.8	13
154	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 1.	0.2	13
155	Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. Immunity, 2022, 55, 1051-1066.e4.	6.6	13
156	The cDNAs encoding two forms of the LYN protein tyrosine kinase are expressed in rat mast cells and human myeloid cells. Gene, 1994, 138, 219-222.	1.0	12
157	CD3Zhypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3Î¶-chain expression in T cells. Rheumatology, 2016, 56, kew405.	0.9	12
158	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. Rheumatology, 2016, 55, 1673-1680.	0.9	11
159	New perspectives on the idiopathic inflammatory myopathies of childhood. Current Opinion in Rheumatology, 1994, 6, 575-582.	2.0	10
160	Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 2.	0.2	10
161	Group A streptococcal infection and Kawasaki syndrome. Lancet, The, 1991, 337, 1100-1101.	6.3	9
162	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology, 2021, 60, 2134-2145.	0.9	9

#	Article	IF	Citations
163	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	1.4	9
164	Parents' perception of self-advocacy of children with myositis: an anonymous online survey. Pediatric Rheumatology, 2011, 9, 10.	0.9	8
165	<scp>47XXY</scp> and <scp>47XXX</scp> in Scleroderma and Myositis. ACR Open Rheumatology, 2022, 4, 528-533.	0.9	8
166	Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. Arthritis Research and Therapy, 2015, 17, 238.	1.6	6
167	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
168	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology, 2022, 61, 2969-2977.	0.9	6
169	Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Rheumatology, 2022, 61, SI48-SI55.	0.9	6
170	Developing international consensus on measures of improvement for patients with myositis. Statistical Methods in Medical Research, 2007, 16, 51-64.	0.7	5
171	Confusion Concerning Multiple Versions of the Childhood Myositis Assessment Scale. Arthritis Care and Research, 2014, 66, 648-648.	1.5	5
172	Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis. Pediatric Rheumatology, 2022, 20, 30.	0.9	5
173	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2016, 18, 156.	1.6	4
174	Clinical research networks: a step towards evidence-based practice in pediatric rheumatology. Nature Clinical Practice Rheumatology, 2007, 3, 59-59.	3.2	3
175	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: Are current therapies just scratching the surface?. Arthritis and Rheumatism, 2010, 62, 2619-2622.	6.7	3
176	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. Arthritis and Rheumatology, 2014, 66, S86-S87.	2.9	3
177	Treatment of calcinosis associated with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. Clinical and Experimental Rheumatology, 2019, 37, 1092-1093.	0.4	3
178	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. Pediatric Rheumatology, 2022, 20, 28.	0.9	3
179	Childhood myositis assessment scale and muscle strength testing in patients with juvenile dermatomyositis: Comment on the article by Huber et al. Arthritis and Rheumatism, 2005, 52, 368-368.	6.7	2
180	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2008, 59, 1197-1198.	6.7	2

#	Article	IF	Citations
181	Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Pediatric Rheumatology, 2014, 12, .	0.9	2
182	Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10RÎ² and IFNAR1 Genes. PLoS ONE, 2013, 8, e67752.	1.1	2
183	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine, 2022, 9, 842586.	1.2	2
184	Does early growth hormone therapy prevent glucocorticoid-associated growth retardation in children with JIA?. Nature Clinical Practice Rheumatology, 2008, 4, 394-395.	3.2	1
185	A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S39-S40.	2.9	1
186	Response to: â€˜Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™â€™ by Irfanet al. Annals of the Rheumatic Diseases, 2023, 82, e41-e41.	0.5	1
187	THU0241â€…Ethnic but not gender differences in disease manifestations in dermatomyositis patients. Annals of the Rheumatic Diseases, 2013, 71, 236.3-236.	0.5	1
188	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	1
189	The relationship of muscle strength and gait performance in children with juvenile idiopathic inflammatory myopathy. Gait and Posture, 1997, 5, 158-159.	0.6	0
190	On Determining the Effects of Therapy on Disease Damage in Non Randomized Studies with Multiple Treatments: A Study of Juvenile Myositis. Communications in Statistics - Theory and Methods, 2009, 38, 3268-3281.	0.6	0
191	P.21.5 Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Neuromuscular Disorders, 2013, 23, 844-845.	0.3	0
192	Progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Journal of the Neurological Sciences, 2013, 333, e458.	0.3	0
193	SAT0376â€…ANTI-NT5C1A autoantibodies are frequent in juvenile myositis and associated with increased illness severity. , 2017, , .		0
194	Response to: â€˜Comment on: â€˜Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositisâ€™â€™ by Sabbagh Set alâ€™by Yanget al. Annals of the Rheumatic Diseases, 2020, 79, e97-e97.	0.5	0
195	Outcomes and Assessment for Inflammatory Muscle Disease. , 2009, , 253-276.		0
196	Distinguishing Disease Activity and Damage in Myositis. , 2020, , 345-354.		0
197	Conflicting reports of antiâ€“cytosolic 5â€²â€nucleotidase <scp>1A</scp> autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld et al. Arthritis and Rheumatology, 2022, 74, 911-912.	2.9	0
198	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	0